Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov;93(11):1600-1610.
doi: 10.1016/j.mayocp.2018.06.026.

The Return of Actionable Variants Empirical (RAVE) Study, a Mayo Clinic Genomic Medicine Implementation Study: Design and Initial Results

Iftikhar J Kullo  1 , Janet Olson  2 , Xiao Fan  3 , Merin Jose  3 , Maya Safarova  3 , Carmen Radecki Breitkopf  2 , Erin Winkler  4 , David C Kochan  3 , Sara Snipes  3 , Joel E Pacyna  2 , Meaghan Carney  3 , Christopher G Chute  5 , Jyoti Gupta  6 , Sheethal Jose  6 , Eric Venner  7 , Mullai Murugan  7 , Yunyun Jiang  7 , Magdi Zordok  3 , Medhat Farwati  3 , Maraisha Philogene  3 , Erica Smith  3 , Gabriel Q Shaibi  8 , Pedro Caraballo  9 , Robert Freimuth  2 , Noralane M Lindor  10 , Richard Sharp  2 , Stephen N Thibodeau  11
Affiliations

The Return of Actionable Variants Empirical (RAVE) Study, a Mayo Clinic Genomic Medicine Implementation Study: Design and Initial Results

Iftikhar J Kullo et al. Mayo Clin Proc. 2018 Nov.

Abstract

Objectives: To identify clinically actionable genetic variants from targeted sequencing of 68 disease-related genes, estimate their penetrance, and assess the impact of disclosing results to participants and providers.

Patients and methods: The Return of Actionable Variants Empirical (RAVE) Study investigates outcomes following the return of pathogenic/likely pathogenic (P/LP) variants in 68 disease-related genes. The study was initiated in December 2016 and is ongoing. Targeted sequencing was performed in 2533 individuals with hyperlipidemia or colon polyps. The electronic health records (EHRs) of participants carrying P/LP variants in 36 cardiovascular disease (CVD) genes were manually reviewed to ascertain the presence of relevant traits. Clinical outcomes, health care utilization, family communication, and ethical and psychosocial implications of disclosure of genomic results are being assessed by surveys, telephone interviews, and EHR review.

Results: Of 29,208 variants in the 68 genes, 1915 were rare (frequency <1%) and putatively functional, and 102 of these (60 in 36 CVD genes) were labeled P/LP based on the American College of Medical Genetics and Genomics framework. Manual review of the EHRs of participants (n=73 with P/LP variants in CVD genes) revealed that 33 had the expected trait(s); however, only 6 of 45 participants with non-familial hypercholesterolemia (FH) P/LP variants had the expected traits.

Conclusion: Expected traits were present in 13% of participants with P/LP variants in non-FH CVD genes, suggesting low penetrance; this estimate may change with additional testing performed as part of the clinical evaluation. Ongoing analyses of the RAVE Study will inform best practices for genomic medicine.

PubMed Disclaimer

Conflict of interest statement

Potential Competing Interests: The authors report no competing interests.

Figures

FIGURE 1.
FIGURE 1.
Participant recruitment for the Return of Actionable Variants Empirical Study in Rochester, Minnesota. LDL-C = low-density lipoprotein cholesterol. To convert LDL-C values to mmol/L, multiply by 0.0259; triglyceride values to mmol/L, multiply by 0.0113.
FIGURE 2.
FIGURE 2.
Selection of actionable genes and single nucleotide variants (SNVs). ACMG = American College of Medical Genetics and Genomics; eMERGE = electronic MEdical Records and GEnomics.
See this image and copyright information in PMC

References

    1. Fossey R, Kochan D, Winkler E, et al. Ethical considerations related to return of results from genomic medicine projects: the eMERGE Network (Phase III) experience. J Pers Med. 2018;81. - PMC - PubMed
    1. Kullo IJ, Jarvik GP, Manolio TA, Williams MS, Roden DM. Leveraging the electronic health record to implement genomic medicine. Genet Med. 2013;15(4):270–271. - PMC - PubMed
    1. Bowen MS, Kolor K, Dotson WD, Ned RM, Khoury MJ. Public health action in genomics is now needed beyond newborn screening. Public Health Genomics. 2012;15(6):327–334. - PMC - PubMed
    1. Khoury MJ, Reyes M, Gwinn M, Feero WG. A genetic test registry: bringing credible and actionable data together. Public Health Genomics. 2010;13(6):360–361. - PMC - PubMed
    1. Knowles JW, O’Brien EC, Greendale K, et al. Reducing the burden of disease and death from familial hypercholesterolemia: a call to action. Am Heart J. 2014;168(6):807–811. - PMC - PubMed

Publication types